Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 16/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117450 | 0.91 | HTR6 (0.53) | ALKCYP19A1HTR6L3MBTL1KDM4E | |
| SCHEMBL3119476 | 0.91 | HTR6 (0.53) | ALKCYP19A1HTR6L3MBTL1KDM4E | |
| SCHEMBL3120267 | 0.89 | CYP19A1 (0.56) | ALKCYP19A1HTR6L3MBTL1KDM4E | |
| SCHEMBL3122898 | 0.89 | LMNA (0.52) | ALKCYP19A1HTR6L3MBTL1KDM4E | |
| SCHEMBL3109112 | 0.88 | CYP19A1 (0.49) | ALKCYP19A1HTR6L3MBTL1KDM4E | |
| SCHEMBL3122486 | 0.85 | NLRP3 (0.52) | ALKCYP19A1HTR6L3MBTL1 | |
| SCHEMBL3110540 | 0.85 | CYP19A1 (0.52) | ALKCYP19A1HTR6L3MBTL1KDM4E | |
| SCHEMBL3110994 | 0.84 | CYP19A1 (0.51) | ALKCYP19A1HTR6L3MBTL1KDM4E | |
| SCHEMBL3121651 | 0.84 | MAPT (0.56) | ALKCYP19A1HTR6KDM4EUBE2N | |
| SCHEMBL3118291 | 0.84 | HTR6 (0.55) | ALKCYP19A1HTR6L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501957-B2 | Benzimidazole compounds and their use as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2013-08-06 | — | — | US | disclosed |
| EP-2397471-A1 | Benzimidazole compounds and their use | China Medical University (TW) | 2011-12-21 | — | — | EP | disclosed |
| US-20100179147-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179147-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | H1-3, BAK1, HDAC1 | ALK 1726/4885CYP19A1 1180/4885HTR6 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.